X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under this collaboration, Johnson & Johnson will provide funding for Rallybio's RLYB212, the sole investigational therapy currently in clinical development aimed at addressing the needs of pregnant individuals at risk of FNAIT.
Lead Product(s): RLYB212
Therapeutic Area: Immunology Product Name: RLYB212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 10, 2024
Details:
RLYB116 is a novel antibody mimetic fusion protein, long-acting C5 inhibitor. It is being evaluated in phase 1 clinical trials for patients with complement-mediated diseases.
Lead Product(s): RLYB116
Therapeutic Area: Immunology Product Name: RLYB116
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Lead Product(s): RLYB212
Therapeutic Area: Immunology Product Name: RLYB212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.
Lead Product(s): RLYB212
Therapeutic Area: Immunology Product Name: RLYB212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2023
Details:
RLYB211 is a polyclonal anti-HPA-1a antibody derived from human plasma, it is being investigated for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Lead Product(s): RLYB211
Therapeutic Area: Immunology Product Name: RLYB211
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.
Lead Product(s): RLYB212
Therapeutic Area: Immunology Product Name: RLYB212
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to polyethylene glycol (PEG).
Lead Product(s): RLYB114
Therapeutic Area: Ophthalmology Product Name: RLYB114
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: EyePoint Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2023
Details:
The results demonstrate that low doses of the two HPA-1a-specific antibodies, the polyclonal candidate RLYB211 and the monoclonal candidate RLYB212, are equally effective at rapidly clearing HPA-1a-positive platelets from circulation and preventing alloimmunization to HPA-1a.
Lead Product(s): RLYB212
Therapeutic Area: Immunology Product Name: RLYB212
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease novel antibody-based therapeutic targets, which will be chosen together by both companies.
Lead Product(s): Antibody-based Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 01, 2022
Details:
Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100 mg dose, with mild or moderate adverse events and no drug-related serious adverse events reported.
Lead Product(s): RLYB116
Therapeutic Area: Rare Diseases and Disorders Product Name: RLYB116
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
